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Glucose transporter-1 protein (GLUT1) and carbonic anhydrase IX (CAIX) are regulated by hypoxia inducible factor-1 (HIF-1) and
have been studied as putative intrinsic cellular markers for hypoxia. This study directly compares CAIX and GLUT1 with
pimonidazole binding in a prospective series of bladder cancer patients and also studies the prognostic significance of the markers, in
combination with vascularity and proliferation, in a retrospective series of bladder cancer patients treated in a phase II trial of radical
radiotherapy with carbogen and nicotinamide (ARCON). A total of 21 patients with a diagnosis of transitional cell carcinoma of the
bladder received 0.5gm
 2 pimonidazole. Serial tumour sections were stained for pimonidazole, GLUT1 and CAIX and compared.
Tissue sections obtained from a series of 64 patients previously treated for invasive bladder cancer using ARCON were stained for
GLUT1 and CAIX together with Ki-67 and CD31/34. There was a good geographical colocalisation of both intrinsic markers with
pimonidazole and a highly significant agreement in individual patients; correlation coefficients were 0.82 (P¼0.0001) for GLUT1 and
0.74 (Po0.0001) for CAIX. In both series of patients, the intrinsic hypoxia markers were highly correlated with each other and a
correlation with proliferation was also evident in the retrospective study. In univariate and multivariate analyses, GLUT1 and CAIX
were independent predictors for overall and cause specific survival. The hypoxia markers did not predict for local control or
metastases-free survival although higher Ki-67 indices showed a trend towards local failure. The data suggest that both hypoxia
modification and accelerated treatment may be valid treatment options in bladder cancer.
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Bladder cancer is common accounting for over 12000 cases each
year in the UK. The muscle-invasive form of the disease is
commonly treated with either radical cystectomy or radical
radiotherapy. The significance of hypoxia in bladder cancer has
been difficult to study due to the limitations of access to oxygen
probe-based technology. Recently, we have shown that many
bladder tumours are hypoxic using prebiopsy administration of
pimonidazole and immunohistochemical staining for bound
pimonidazole fragments after nitroreductase-induced breakdown
in hypoxic areas (Wykoff et al, 2000). The disadvantage of the use
of pimonidazole as a marker of hypoxia is the need to administer
the drug several hours prior to biopsy and thus an intrinsic
immunohistochemical marker of hypoxia would have considerable
advantages over this extrinsic method.
There are several putative intrinsic markers of hypoxia under
investigation whose common theme is regulation by hypoxia
inducible factor-1 (HIF-1) (Semenza, 2000). Of these, two proteins,
carbonic anhydrase IX (CAIX) and glucose transporter-1 protein
(GLUT1), have received much recent attention (Airley et al, 2001,
2003; Chia et al, 2001; Giatromanolaki et al, 2001; Loncaster et al,
2001; Olive et al, 2001; Swinson et al, 2003). In an initial series of
bladder cancers, CAIX was found to colocalise with pimonidazole
(Wykoff et al, 2000). More recently, in superficial and muscle-
invasive bladder cancer there was overlap in the expression of
vascular endothelial growth factor (VEGF) and CAIX, CAIX being
more widespread (Turner et al, 2002). It was noted that the
expression of CAIX was absent within 80mm of microvessels and a
similar experience has now been reported with GLUT1 in cervical
cancer (Airley et al, 2001).
This investigation consists of two arms. The first utilised a series
of prospective bladder cancer patients who were studied with
pimonidazole administration to establish the correspondence
between cellular hypoxia and CAIX and GLUT1 distributions.
Second, tumour specimens from a cohort of patients with detailed
clinical outcome treated in a phase II trial of carbogen and
nicotinamide (Hoskin et al, 1999) in the radical radiotherapy of
bladder cancer, have been reviewed and stained with GLUT1,
CAIX, Ki-67 and the combined vascular markers CD31 and CD34.
The results of this have been explored in relation to treatment
outcome.
MATERIALS AND METHODS
Patients and treatments
The prospective cohort comprised 21 patients with a diagnosis of
transitional cell carcinoma of the bladder who were to undergo Revised 1 July 2003; accepted 8 July 2003
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ydefinitive transurethral resection of bladder tumour (TURBT).
With appropriate approval from the Local Ethics Committee for
Mount Vernon Cancer Centre, patients received 0.5gm
 2 pimo-
nidazole (Hydroxyprobe-1t, Natural Pharmacia Inc., Belmont,
MA, USA) administered in 100ml of normal saline by intravenous
infusion over 15min, 8–18h prior to biopsy. Tumour samples
taken at TURBT were fixed in formalin, protected from light and
stored at 41C.
The retrospective series of patients had been treated at Mount
Vernon Hospital in a phase II trial of radical radiotherapy with
carbogen and nicotinamide. The patients received 50–55Gy in 20
daily fractions over 4 weeks with carbogen breathing delivered at a
rate of 15lmin
 1 through a sealed face mask and a closed
breathing system with a one-way valve, started 5min prior to
radiotherapy and maintained throughout treatment; only four
patients failed to tolerate the whole course of carbogen breathing.
A total of 33 patients also received nicotinamide (80mgkg
 1)
given orally at least 1h after eating and 1.5h prior to radiotherapy;
31 patients did not receive nicotinamide either due to coexisting
vascular disease or patient refusal. Approval from the Local Ethics
Committee for Mount Vernon Cancer Centre was granted to
approach these patients for permission to use samples of their
stored original biopsy material for further analysis. A total of 64
samples was finally obtained and analysed. The characteristics of
these patients are shown in Table 1.
Immunohistochemistry
In the prospective study, pimonidazole, CAIX and GLUT1 were
stained on serial sections using single-staining procedures.
Staining for pimonidazole both alone and in combination with
proliferation and vascular markers have been reported separately
(Hoskin et al, 2003 (submitted)) Briefly, after dewaxing and
rehydration, the sections were pretreated with 0.01% Pronase
(Sigma Poole, Dorset UK) in PBS pH 7.8 at 371C for 10min.
Endogenous peroxidase was blocked using Dako peroxidase block
for 5min and then Dako protein block was applied for 5min after
washing in tap water. Mouse anti-pimonidazole IgG1 monoclonal
antibody (Clone Hypoxyprobet-1MAb1: Natural Pharmacia Inc.)
was diluted 1/100 in Tris-buffered saline (TBS, 0.01 M Tris-HCl,
0.14 M NaCl, pH 7.6) and incubated for 30min at room
temperature, this was followed, after washing, by Envision HRP
Mouse polymer (Dako High, Wycombe, Bucks, UK) for a further
30min. After washing, diaminobenzidine (DAB) substrate (7.5mg
DAB (Vector, Peterborough UK), 10ml 0.1 M Tris buffer, 1 drop
3% H2O2) was added for 5min. The slides were rinsed in TBS and
then running tap water and placed briefly in Mayer’s haematoxylin
and mounted in DPX (Merck 360294H). GLUT1 required
microwave pretreatment in 10mM citric acid pH 6.0 on high
power for a total of 12min (4 3min). CAIX required no
pretreatment. The remainder of the staining procedures were the
same, the anti-GLUT1 antibody (Dako Hyh, Wycombe, Bucks, UK)
was diluted at 1/200 and anti-CAIX (a gift from Adrian Harris,
Oxford) was used at a dilution of 1/50.
In the retrospective study to maximise the potential informa-
tion, each cohort of patients was examined using serial sections
and a series of double-staining procedures that consisted of either
CAIX or GLUT1 in combination with either Ki-67 or CD31/CD34.
The combinations of substrates were governed by the Envision
Alkaline Phosphatase (AP) polymer that was only available in anti-
mouse form. Therefore, as the GLUT1 and Ki-67 antibodies were
polyclonal, the following combinations were used: CAIX (AP)/Ki-
67 (HRP), CAIX (HRP)/CD31 (AP) and GLUT1 (HRP)/CD31 (AP).
As the CAIX antibody required no pretreatment, it was incubated
first when in combination using either Envision horseradish
peroxidase (HRP) Mouse polymer (Dako) for 30min followed by
DAB substrate for 5min (when used with CD31) or Envision AP
(Dako) for 30min followed by the addition of the AP Red substrate
(Vector, Peterborough UK) for 5–10min (when used with Ki-67).
After washing, microwave pretreatment in10mM citric acid pH 6.0
on high power was performed for a total of 12min (4 3min)
Either rabbit anti-human Ki-67 antibody (Dako) diluted 1/200 or
mouse anti-CD31/CD34 antibody cocktail (Dako M0823/M7080)
diluted 1/50 and 1/100 was incubated in TBS for 1h at room
temperature. Then, the appropriate Envision polymer and
substrate was added as described above to visualise the second
antigen. The sections were rinsed in TBS and washed well in
running tap water. The sections were counterstained lightly in Gills
haematoxylin between 10 and 60s and then washed well in tap
water. Finally, the sections were dehydrated through graded
alcohols, cleared by xylene and sections mounted in DPX. For
GLUT1 and CD31/34, microwave pretreatment was undertaken at
the start of the procedure and GLUT1 was then visualised using the
Envision HRP and DAB combination followed by CD31/34 using
the Envision AP and Vector red combination as described above.
Image capture
Images were captured using an Axioscope trans-illumination
microscope (Zeiss) connected to a 3-CCD colour camera (JVC).
Images were digitised with a Matrox Meteor frame grabber in a PCI
bus 600MHz Pentium desktop PC. Analysis was performed using
routines developed in Visilog 5.02 software (Noesis Vision Inc,
Lesvlis Cedex, France). Image-capture procedures were standar-
dised for light intensity and background subtraction at different
magnifications. There was no automated analysis of data, but
simple tools (area measurement, line measurement, counting
grids), developed in Visilog 5.02 software, were used to comple-
ment visual identification and scoring.
Immunohistochemical analysis
As hypoxia-related markers tended to be expressed in contiguous
cells, the area of pimonidazole, CAIX and GLUT1 staining was
assessed at  100 ( 10 eyepiece and objective) using a tool that
enabled manual drawing of regions around the stained cells, the
overall tumour area and necrosis; this made possible the exclusion
of stroma. Two sections from each tumour were systematically
assessed and between 3 and 45 fields were viewed for each
specimen. The fraction of cells stained for hypoxia was expressed
as a percentage of the total tumour area.
Geographic colocalisation was assessed semiquantitatively by
visual inspection of stained areas in serial sections.
The proliferative index was assessed from Ki-67 staining in the
retrospective series by computer-aided manual counting of multi-
ple fields ( 400) captured from two sections of each tumour.
Table 1 Patient characteristics
Prospective
pimonidazole study
Retrospective
carbogen patients
Age (years) 70 (49–87) 73 (38–88)
Median(range)
Stage
T1 3 6
T2 5 19
T3 12 38
T4 1 1
Grade
G1 1 2
G2 10 17
G3 10 55
Total 21 64
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vascular density. The sections were systematically surveyed for a
‘hot spot’ of vessels using a  5 objective. The ‘hot spot’ was then
centralised in the microscope field, viewed under a final
magnification of  200 and individual vessels were counted.
Between three and 10 hot spots were counted for each tumour,
depending on the size of the section. The highest hot spot count
was assigned to the tumour. Vascular density involved simply
counting all vessels at  100 magnification in multiple fields from
two sections of each tumour. This represented a field size of
0.710mm
2. The vascularity was expressed as the number of vessels
per mm
2 of tissue section.
Statistical analysis
The relationships between biological parameters (as continuous
variables) and T stage and grade were tested using one-way
analysis of variance and the w
2 test. The biological parameters were
compared by either the Spearman rank correlation coefficient for
continuous variables or by w
2 statistic. Survival intervals were
calculated using the Kaplan–Meier product limit method. In the
calculation of local recurrence-free survival and metastasis-free
survival, nonfailures were censored at last follow-up or at death.
For cause-specific survival, patients who died as a result of bladder
cancer were classed as failures and nonfailures and were censored
at death from other causes or at the last follow-up. For overall
survival, patients who died of any cause were classed as failures
and non-failures and were censored at the last follow-up. All time
intervals were calculated from the date of first radiotherapy
treatment. Individual factors were tested using the log rank test,
where Po0.05 was considered significant. The Cox proportional
hazard model was used for multiple regression analysis.
RESULTS
Staining patterns for pimonidazole, CAIX and GLUT1 in
the prospective study
There was considerable intra- and intertumour variation in both
the amount and intensity of staining for each of the three hypoxia-
associated markers. Staining with pimonidazole was both cyto-
plasmic and nuclear and tended to be contiguous, but some focal
hypoxia was noted, and even single-cell staining was seen. The
darkest staining intensity was consistently seen adjacent to
necrotic regions, but there were also other regions of dark staining
unassociated with necrosis within tumour sections. CAIX and
GLUT1 staining was predominantly membranous and was strongly
associated with areas adjacent to necrosis and there was a paucity
of staining near blood vessels. Geographical colocalisation of
pimonidazole, CAIX and GLUT1 was assessed by visual inspection.
The majority of tumours showed similar staining patterns for the
three markers with the exception of one tumour that stained
extensively for pimonidazole but minimally for both GLUT1 and
CAIX, while another showed no pimonidazole binding but
substantial GLUT1 and CAIX staining. Concordant localisation is
exemplified in Figure 1, which demonstrates closely matched areas
where CAIX and GLUT1 showed identical expression within a
region that bound pimonidazole. In this case, the binding of
pimonidazole was more extensive than the intrinsic markers, but
this was variable between tumours. Colocalisation was prevalent
but there were also regions of mismatch, more often where
pimonidazole and GLUT1 were both positive and CAIX was
negative.
In the prospective series of patients, the median stained fraction
and range of values for pimonidazole, GLUT1 and CAIX was 9%
(0–38%), 15% (0–45%) and 12% (0–35%), respectively. Three
tumours failed to demonstrate any pimonidazole binding, while
only one was negative for GLUT1 and two did not express CAIX.
The markers were all highly correlated with each other (Table 2,
Figure 2), but Figure 2 highlights that in box 2 there were tumours
that showed expression of the extrinsic marker in the absence of
the intrinsic markers and vice versa in box 3.
Biological parameters in the retrospective study
In the retrospective group of patients the median hypoxic fraction
as defined by GLUT1 was 6.5% (range 0–62%) compared to 3.5%
(range 0–67%) with CAIX (Table 3). Again, there was a strong
correlation between CAIX and GLUT1 (Table 2, Figure 3).
However, there were differences between this series and the
prospective patients notably in the proportion of tumours that
Figure 1 Serial sections stained for pimonidazole (top), GLUT1 (middle)
and CAIX (bottom).
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series, there were 22 (34%) tumours that were negative for both
CAIX and GLUT1 and a further five were without CAIX staining,
but had low levels of GLUT1 expression. Interestingly, the absolute
levels of both CAIX and GLUT1 positivity was similar in both the
prospective and retrospective series in those tumours which
expressed the proteins (Figure 3).
Figure 4 shows examples of dual staining from which the data in
Table 3 were obtained. In general, there was close geographical
concordance of GLUT1 and CAIX as was noted in the prospective
study. Although not a formal part of this study, it was noted that
both CAIX and GLUT1 tended to stain closer to blood vessels than
pimonidazole and that there was an overlap between these markers
and Ki-67. The median positivity of 35.7% for Ki-67 represents a
value that is indicative of rapid proliferation characteristics.
Interestingly, although there was considerable variation in GLUT1
and CAIX both within and between individual tumours, prolifera-
tion and vascular parameters showed less variation. Correlation
analysis had already revealed a highly significant association
between CAIX and GLUT1 (Table 2), but there was no correlation
between these markers and vascularity assessed by either vascular
Figure 4 Examples of double staining. Serial sections showing similar
areas stained for CAIX (brown) vs CD31/34 (red) (upper), CAIX (red) vs
Ki-67 (brown) (middle), and GLUT1 (brown) vs CD31/34 (red) (lower).
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Figure 2 Comparison between intrinsic and extrinsic markers of
hypoxia. The data are presented as the intrinsic markers subtracted from
the pimonidazole score for each tumour in the prospective study. Box 1
indicates good absolute agreement, while boxes 2 and 3 represent disparity
between the markers.
Table 2 Linear regression and correlation analysis of the intrinsic and
extrinsic hypoxia markers in the prospective and retrospective studies
Parameters Slope Intercept r
2 P-value
Pimo vs CAIX 0.69 +4.8 0.74 o0.0001
Pimo vs GLUT1 0.76 +3.7 0.82 o0.0001
CAIX vs GLUT1 prospective 0.91 +1.2 0.91 o0.0001
CAIX vs GLUT1 retrospective 0.90  0.8 0.96 o0.0001
Pimo¼pimonidazole; CAIX¼carbonic anhydrase IX; GLUT1¼glucose transporter-
1 protein.
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Figure 3 Correlation between GLUT1 and CAIX in the prospective
(K) and retrospective (n) studies.
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correlation between GLUT1 and Ki-67 (Spearman’s
correlation¼0.294, P¼0.018) and a near-significant correlation
between CAIX and Ki-67 (Spearman’s correlation¼0.24,
P¼0.056). Figure 5 shows that this was not a strong relationship,
but proliferation was significantly higher in those tumours with the
highest levels (410%) of both GLUT1 (P¼0.025) and CAIX
(P¼0.029) compared to those tumours that were either negative or
had low levels of expression. Vascularity showed no association
with proliferation, but ‘hot spot’ count did correlate with overall
vascular density (Spearman’s correlation¼0.65, P¼0.0001).
Correlation with clinicopathological features and outcome
None of the biological parameters, in either study, were related to
disease stage, grade or patient age.
Table 4 shows the data obtained using the median value of each
parameter as a cutoff for univariate analysis for a series of clinical
outcome end points. None of the parameters had a significant
influence on local control or time to metastasis; the only trend was
that rapid proliferation was associated with worse local control. In
contrast, there was a highly significant difference in the overall and
cause-specific survival when patients were stratified according to
the intrinsic markers of hypoxia. The 5-year overall survival rate in
tumours expressing higher than median values of GLUT1 was 32%
compared to 72% with low levels; the figures were 35% and 71%
for CAIX. This analysis was taken a step further and the patients
were delineated into three groups, those that were negative for
either GLUT1 or CAIX and the positive tumours were stratified
above or below a value of 10%. The data are presented in Figure 6.
These curves show that tumours without evidence of hypoxia-
associated marker expression have the best survival prospects,
suggesting that these are genuinely negative tumours and not
attributable to sampling error. Low GLUT1 or CAIX is associated
with intermediate survival, while 5-year survival rates of 25% were
estimated for those patients in which either hypoxia surrogate
marker exceeded 10%; this represented 29 (39%) and 22 (34%)
patients for GLUT1 and CAIX, respectively.
Multivariate analysis was undertaken using the biological
parameters as continuous variables in combination with age, T
stage and grade; CAIX and GLUT1 were entered both individually
and together. None of the parameters showed independent
significance for local control. For both cause-specific and overall
survivals, CAIX and GLUT1 showed high independent significance
when entered into the analysis individually. The risk ratios (RR)
for the overall survival were 3.21 (95% CI 1.16–10.22; P¼0.02) for
CAIX and 3.14 (95% CI 1.23–10.09; P¼0.03) for GLUT1. Similar
results were obtained for cause-specific survival. When both
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Figure 5 Relationship between the proliferation and expression of CAIX
and GLUT1. The data show the individual values for Ki-67 positivity and the
mean and s.e.m. for the three categories of intrinsic marker expression.
Table 3 Distribution of biological parameters in the retrospective study
Parameter Median (mean) Range CV
GLUT1 3.5 (11.3) 0–67 129.4
CAIX 6.5 (9.4) 0–62 145.3
Ki-67 35.7 (34.9) 2.6–61.7 35.6
Hot spot 30 (31.5) 12–55 34.3
Vascular density 55.8 (66.4) 21–180 54.4
GLUT1¼glucose transporter-1 protein; CAIX¼carbonic anhydrase IX;
CV=coefficient of variation.
Table 4 Univariate analysis of biological parameters in relation to various clinical endpoints
End point
Local control Time to distant metastastis Cause-specific survival Overall survival
Parameter v
2 P-value v
2 P-value v
2 P-value v
2 P-value
GLUT1 1.56 0.21 0.22 0.64 5.84 0.016 8.06 0.0045
CAIX 0.82 0.36 0.29 0.59 4.16 0.041 8.57 0.0034
Ki-67 2.23 0.14 1.39 0.24 0.63 0.43 0.006 0.94
MVD 0.068 0.79 0.011 0.92 0.002 0.96 0.07 0.79
Hot spot 1.40 0.23 0.013 0.91 0.57 0.45 0.001 0.98
GLUT1¼glucose transporter-1 protein; CAIX¼carbonic anhydrase IX. Each parameter was categorised according to the median value; MVD=mean vascular density.
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CAIX 2.12 (95% CI 0.39–10.94); GLUT1 2.12 (95% CI 0.36–10.33),
suggesting that they are interchangeable as prognostic markers
and that either CAIX or GLUT1 is predictive, but this is not refined
by the addition of the second marker.
DISCUSSION
Hypoxia in tumours is primarily a pathophysiological consequence
of a structurally and functionally compromised microcirculation
and the deterioration of diffusion conditions. Hypoxia appears to
be strongly associated with tumour propagation, malignant
progression and resistance to therapy, and it has thus become a
central issue in tumour physiology and cancer treatment (Brown,
2000; Hockel and Vaupel, 2001; Harris, 2002). An overview analysis
showed that modification of tumour hypoxia significantly
improved the locoregional tumor control after radiotherapy in
head and neck (H&N) cancer and to a lesser extent in bladder
tumours (Overgaard and Horsman, 1996). However, unlike H&N
cancer (Nordsmark et al, 1996; Brizel et al, 1997), it was not
possible to confirm the presence and clinical significance of
hypoxia in bladder cancer due to the inaccessibility of the tumour
site for oxygen electrode-based measurements. The availability of
histological markers of hypoxia has widened the opportunity to
study tumours in more remote sites. The binding of pimonidazole
adducts is perhaps the most robust and widely accepted marker of
cellular hypoxia (Varia et al, 1998; Nordsmark et al, 2001; Raleigh
et al, 2001; Kaanders et al, 2002). However, the technique is
invasive as it requires an injection of pimonidazole to be scheduled
prior to surgical procedures. To circumvent this, there has been a
growing interest in studying hypoxia-regulated proteins as
potential surrogates for the more invasive techniques. These have
included HIF-1a and HIF-2a (Beasley et al, 2002), VEGF (Salven
et al, 1997), GLUT1 and GLUT3 (Younes et al, 1997; Airley et al,
2001; Baer et al, 2002) and CAIX (Loncaster et al, 2001; Swinson
et al, 2003). In the prospective arm of this study, we have
demonstrated that pimonidazole, GLUT1 and CAIX show a high
degree of overlap in their tumour localisation pattern and a
significant correlation in their interpatient comparison. In
addition, in the retrospective study of patients treated by
ARCO(N), both GLUT1 and CAIX overexpression were signifi-
cantly associated with worse cause-specific and overall survivals
but not local control.
Validation of proteins such as CAIX or GLUT1 as intrinsic
markers of cellular hypoxia is clearly important to facilitate the
routine study of tumour hypoxia in clinical trials and ultimately to
use this to direct clinical practice outside trials. Several studies
have attempted to achieve this goal. Airley et al (2003) undertook a
direct comparison of all three markers in cervix cancer specimens.
The study concluded that there were similar staining patterns for
all three markers and that they were significantly correlated with
each other, although this comparison was made on a semiquanti-
tative scoring system. Other studies have shown a weak but
significant correlation between GLUT1 and pO2 values in cervix
cancer (Airley et al, 2001), a strong correlation between CAIX and
pO2 values in cervix cancer (Loncaster et al, 2001) and a weak
correlation between CAIX and pimonidazole in H&N cancer
(Kaanders et al, 2002). The general consensus from these studies is
that expression of both CAIX and GLUT1 might be potential
surrogates for hypoxia. Interestingly, CAIX was predictive of both
disease-free and metastasis-free control but not local control, while
GLUT1 only had a significant association with metastasis-free
survival in similar cervix cancer patients (Airley et al, 2001;
Loncaster et al, 2001). CAIX was without clinical significance in
H&N cancer in contrast to pimonidazole binding that predicted for
locoregional control and disease-free survival (Kaanders et al,
2002).
In bladder cancer, we have previously shown concordance
between CAIX and pimonidazole staining patterns (Wykoff et al,
2000). Other studies have demonstrated that GLUT1 expression is
not seen in normal bladder mucosa, but is present in malignant
bladder mucosa with greater expression seen in muscle-invasive
tumours compared to superficial bladder cancer (Chang et al,
2000). In this study, there was no correlation between recurrence
and GLUT1 expression. CAIX expression was noted to be greater
in superficial disease compared to invasive disease (Turner et al,
2002) and to show siginificant overlap with VEGF mRNA
expression; CAIX did not predict outcome in superficial disease.
In contrast, another study of patients treated by cystectomy for
muscle-invasive bladder cancer found a significantly worse overall
survival if they had 410% GLUT1-stained fraction compared to
those with less staining (Younes et al, 2001).
This study demonstrates that bladder cancer is a tumour with an
average hypoxic fraction of around 10% and we have now shown
that intrinsic markers of hypoxia, both GLUT1 and CAIX, can be
used to predict survival. Accordingly, bladder cancer can be seen
alongside cervical cancer, H&N cancer and soft-tissue sarcomas as
a tumour in which hypoxia is a predictive factor for survival. No
correlation was seen, however, between hypoxia and local control
or metastases-free survival. This finding may be explained by the
fact that all tumours in this group were treated using a hypoxia-
0 2 04 06 08 0 1 0 0
0.2
0.4
0.6
0.8
1.0
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
Time (months)
Negative
<10%
>10%
0 2 04 06 08 0 1 0 0
0.0
0.2
0.4
0.6
0.8
1.0
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
Time (months)
Negative
<10%
>10%
P=0.0012 
P=0.0021 
Figure 6 Influence of GLUT1 (upper panel) and CAIX ( lower panel) on
the overall survival of patients treated with radical radiotherapy, carbogen
and nicotinamide. The data were classified into tumours with no expression
of the proteins and using a cutoff of 10% for those that were positive.
GLUT1 and CAIX as intrinsic markers of hypoxia
PJ Hoskin et al
1295
British Journal of Cancer (2003) 89(7), 1290–1297 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ymodifying regimen that included the administration of carbogen
and nicotinamide (Hoskin et al, 1997; Hoskin et al, 1999). As a
consequence, any negative influence of hypoxia on the outcome
from radiotherapy may have been overcome.
In this series, there was a weak correlation between the Ki-67
index and local control. Other studies that have used Ki-67 as a
marker of proliferation in transitional cell bladder cancer have
reported a significantly lower progression-free and disease-specific
survival rates in patients with higher Ki-67 indices (Popov et al,
1997; Lara et al, 1998; Moonen et al, 1998a; Rodel et al, 2000).
Clinical data relating the effect of treatment duration on bladder
outcome are equivocal (Maciejewski and Majewski, 1991; De Neve
et al, 1995; Moonen et al, 1998b).
The data from this study establish that muscle-invasive bladder
cancer is a relatively rapidly proliferating, hypoxic tumour where a
rationale for alternative treatments such as ARCON is justified. To
maximise the benefit of ARCON, it may be possible to consider
individualisation of treatment on the basis of intrinsic immuno-
histochemical markers of hypoxia and proliferation, which can be
performed on routine paraffin-embedded biopsy material. Valida-
tion of such an approach requires evaluation in a randomised
cohort of patients that is currently being undertaken in the
multicentre BCON trial of carbogen and nicotinamide in bladder
cancer.
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